Serina Therapeutics OK on IND Application for SER-252 for Parkinson’s

Serina Therapeutics (NYSE American: SER) announced FDA clearance of its IND application for SER-252, enabling initiation of site‑level and regulatory activities to start a planned Phase 1b registrational study in advanced Parkinson’s disease. The company noted prior FDA feedback and alignment on a 505(b)(2) NDA pathway.

https://www.stocktitan.net/news/SER/serina-therapeutics-announces-fda-clearance-of-ind-application-for-p8h7qea4xz12.html